CD33 and acute myeloid leukemia: These include midostaurin for FLT3 mutant AML, venetoclax for raised BCL2 AML, ivosidenib/enasidenib for IDH mutant AML or gemtuzumab ozogamicin for CD33+ AML [3,4].